Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral vaccine aims to boost immune attack on aggressive breast cancer

NCT ID NCT06631092

Recruiting now Disease control Sponsor: NEC Bio B.V Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and helps the immune system target the cancer more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
personalized oral DNA cancer vaccine (NECVAX-NEO1)
What this could lead to
If successful, this could lead to a new add-on treatment that helps the immune system better fight triple-negative breast cancer, potentially improving outcomes when combined with standard therapy.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply broadly. The vaccine is personalized, which is complex and may not work for everyone. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • National Center for Tumor Diseases Heidelberg

    RECRUITING

    Heidelberg, Germany

    Contact Email: •••••@•••••

  • University Clinic Erlangen

    RECRUITING

    Erlangen, Germany

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.